


**Akt/mTOR integrate energy metabolism with Wnt signal to influence wound epithelium growth in *Gekko Japonicus***

Qinghua Wang, Zuming Mao, Zhuang Liu, Man Xu, Shuai Huang, Yin Wang, Yanran Xu, Longju Qi, Mei Liu, Yan Liu


Supplementary figures

Supplementary Figure 1 Wnt pathway promoted Akt activity and enhanced FGFs expression in blastema cells




**a**, Wnt agonist (SKL2001 or CHIR) promoted Akt phosphorylation in cultured blastema cells. **b-c**, Relative level of p-Akt (Thr308)/Akt and p-Akt (Ser473)/Akt in **Supplementary Fig. 1a**. **d**, The transcriptional expression of FGF8, FGF10 and FGF20 were enhanced in SKL2001 treated blastema cells, while attenuated by administration of MK-2206 (Akt antagonist), N=3. Values represent mean  $\pm$  SD, <sup>ns</sup>  $p > 0.05$ , \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

**Supplementary Figure 2 Wnt agonist partially rescued the deficit of wounding epithelium formation in low temperature during tail regeneration.**



**a**, Wounding epithelium positively stained with WE6 antibody were observed at day 7 post tail amputation in normal temperature. **b-c**, The epithelium formation was inhibited in low temperature, while the treatment of Wnt agonist CHIR gave rise to partial formation of epithelium at day 7 post tail amputation in low temperature. **d-e**, The treatment of CHIR that produced partial epithelium could not proceed and complete regeneration after 14 days post amputation in low temperature condition. **a'-e'** were the enlarged views of boxed areas in **a-e**, respectively. Solid line indicates the caudal border of wound epithelium, dotted line indicates border between wound epithelium and blastema.



**Supplementary Fig. 3 mTOR inhibition by Torin1 hindered the regeneration wound epithelium**






**a**, Formation of wound epithelium (WE) in the control (DMSO) and mTOR inhibition groups (Torin1). **b**, Number of geckos with regeneration in control and Torin1 groups. N=10. **c**, Protein level of p-mTOR (Ser2448), and mTOR in tail tissues. **d**, Relative level of p-mTOR (Ser2448)/mTOR. N=3. **e**, Immunofluorescence analysis of BrdU staining in DMSO and Torin1 group (upper panel). Immunohistochemical analysis of WE6 staining in the same location of the samples (lower panel). Scale bar = 100µm. Solid line indicates border between wound epithelium and scab, and dotted line indicates border between rostral end of wound epithelium and blastema. **f**, Number of BrdU positive cells in control and mTOR inhibition groups. N = 5. Values represent mean ± SD, ns  $p > 0.05$ , \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .


Supplementary Fig. 4 Uncropped immunoblots

Raw immunoblotted films for Figure 2



















Raw immunoblotted films for Figure 3






Raw immunoblotted films for Figure 5







Raw immunoblotted films for Figure 6










Fig.6 b-actin




Raw immunoblotted films for Figure 7















Raw immunoblotted films for Supplementary Figure 1






Raw immunoblotted films for Supplementary Figure 3



Supplementary Fig.3 mTOR



mTOR